Organogenesis to open $100M biotech facility in Rhode Island, will resume Dermagraft production
The company will produce its FDA-approved diabetic foot ulcer product and others at the new facility, creating over 200 full-time jobs.
Organogenesis, a regenerative medicine company focused on wound care, is planning a new biomanufacturing facility in Smithfield, Rhode Island.
The expected $100M, 122,000 square-foot facility will accommodate manufacturing, laboratory, warehouse, and distribution operations, and resume production of its FDA-approved therapy for diabetic foot ulcers, Dermagraft.
Dermagraft is a human fibroblast-derived dermal substitute (HFDS) made of a cryopreserved, absorbable, three-dimensional polyglactin mesh substrate seeded with living neonatal dermal fibroblasts.
Get Regen Report in your inbox
Weekly updates on regenerative medicine news, trials, and regulatory moves.
Here’s the Science Direct article explaining the product:
https://www.sciencedirect.com/topics/engineering/dermagraft?__cf_chl_tk=pCzEII_wrmJUjQ7f65ZO1HSGuqXmYASRyje_Ii.gyL8-1747967145-1.0.1.1-WERhJ27HgBMyldIKblxczQa.I9tfl3GXjJ724V9wwhE
That’s all, short one for today ☺.
